Bioline RX (NASDAQ:BLRX) has been assigned a $4.00 price target by investment analysts at HC Wainwright in a report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 277.36% from the stock’s previous close.
Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Bioline RX from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. ValuEngine upgraded Bioline RX from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Maxim Group set a $3.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, Oppenheimer set a $3.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Monday, December 4th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Bioline RX presently has a consensus rating of “Hold” and a consensus target price of $2.88.
Shares of Bioline RX (NASDAQ:BLRX) traded down $0.02 during trading hours on Wednesday, reaching $1.06. The company’s stock had a trading volume of 1,489,056 shares, compared to its average volume of 813,701. Bioline RX has a 52-week low of $0.80 and a 52-week high of $1.38. The company has a market capitalization of $114.77, a PE ratio of -3.21 and a beta of 0.88.
ILLEGAL ACTIVITY WARNING: “Bioline RX (BLRX) PT Set at $4.00 by HC Wainwright” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/17/bioline-rx-blrx-pt-set-at-4-00-by-hc-wainwright-2.html.
About Bioline RX
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.